Glucose Monitoring Global Market – Forecast to 2023

Publishing Date : June, 2017
Report Code : HCMD0148
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Glucose Monitoring consist of products that are essential for patients suffering diabetes. With the projected rise in aged population and awareness about such conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the Glucose Monitoring global market is expected to grow at single digit CAGR to reach $11,248.5 million by 2023. Factors driving the Glucose Monitoring market are global rise in the prevalence and incidence of diabetes, continuous technological advancement, increasing demand for less invasive products, and increase in R&D investments are driving the market growth. Increase in obesity population due to lifestyle changes, increase in urbanization, untapped markets like Middle East, Africa shows that glucose monitoring market has vast opportunities in the coming years. Frequent product recalls i.e. glucose testing strips due to manufacturing defects or supply of expired test strips and less product differentiation among the self blood glucose monitors are the factors that are restraining the market growth. The limited reimbursement facilities and alternative treatments that include cell based assays, biomarkers identification and artificial pancreas and high cost associated with Continuous Glucose Monitoring (CGM) are threats for the market growth.


Glucose Monitoring global market is classified based on products, sample type, end-users and geography. The products segment is divided into three segments i.e., Invasive, Non-Invasive and lab based glucose monitoring products. The Invasive glucose monitoring products segment accounted the largest share in 2016 due to technological advancements, easy use, patient friendly etc. Invasive products are classified into Self glucose monitoring and continuous glucose products. The self glucose monitoring segment accounted the largest share in 2016 due to development of minimally invasive products. The Self glucose monitoring products are further classified into blood glucose monitors, blood glucose test strips, lancets and others. The blood glucose testing strips segment accounted for the largest share in 2016 due development of no coding strips. The continuous glucose monitoring market includes sensors/receiver and transmitter. The continuous glucose market includes products sensors/receiver and transmitter. Continuous glucose segment is fastest growing segment and is projected to grow at a strong CAGR of XX% from 2016 to 2023.

Based on sample type the market is segmented into blood, urine and others. The blood segment accounted the largest share in 2016 and is projected to grow at a CAGR of 0.3% from 2016 to 2023 due to the accuracy of results. Other source based glucose monitoring segment is fastest growing segment and is projected to grow at a strong CAGR of XX% from 2016 to 2023 due to increases R & D investment, many product are CE approved and expected  launch very soon in market.

Based on end users the market is segmented into hospitals, private clinics, home care and ambulatory settings. Among end-users, home care segment accounted for the largest share in 2016 and is projected to grow at a strong CAGR of X% from 2016 to 2023 due to availability of self blood monitor over the counter and ease in operating these monitors and thereby reduces dependence on any clinics for glucose check.

Based on geography the market is segmented into North America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-Pacific (Japan, China, India and Others) and Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the highest market share of XX% followed by Europe. The steep rise in aging population, advancement in technology, awareness of people about treatment options and favorable government policies are driving factors of glucose monitoring market. However, Asian countries especially India and China are the fastest growing regions with its growing demand for glucose monitoring products.

Major players in Glucose monitoring market include Roche (Switzerland), Dexcom (U.S.), B. Braun Melsungen AG (Germany), Medtronic, Inc. (Ireland), Johnson & Johnson (U.S.), Abbott Laboratories (U.S.), AgaMatrix (U.S.), Arkray (Japan), Ascensia (Switzerland), Trividia Health, Inc (U.S.) etc.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Others

• Europe
o Germany
o U.K.
o France
o Others

• Asia-Pacific
o Japan
o China
o India
o Others

• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle-East (Middle East & Others)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1      GLOBAL RISE IN THE PREVALENCE AND INCIDENCE OF DIABETES
        • 3.3.1.2      CONTINUOUS TECHNOLOGICAL ADVANCEMENTS IN GLUCOSE MONITORING DEVICES
        • 3.3.1.3     INCREASING DEMAND FOR LESS INVASIVE DEVICES OR POINT OF CARE
        • 3.3.1.4     INCREASING R & D INVESTMENTS
      • 3.3.2     RESTRAINS AND THREATS
        • 3.3.2.1     AVAILABILITY OF ALTERNATIVE TREATMENT
        • 3.3.2.2     HIGH COST ASSOCIATED WITH THE PRODUCTS
        • 3.3.2.3     INADEQUATE REIMBURSEMENT
        • 3.3.2.4     PRODUCT RECALLS
        • 3.3.2.5     STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE FDA AND OTHERS.
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
    • 3.6     PATENT ANALYSIS
    • 3.7     TECHNOLOGY ADVANCEMENTS
      • 3.7.1     NO-STRIP TECHNOLOGY
      • 3.7.2     NO-CODING TECHNOLOGY
      • 3.7.3     SOURCE ADVANCEMENTS
      • 3.7.4     WEARABLE OR WIRELESS TECHNOLOGY
    • 3.8     UPCOMING TECHNOLOGY AND PRODUCT LAUNCH
    • 3.9     FUNDING SCENARIO
    • 3.10     GLUCOSE MONITORING - DEALS
    • 3.11     CLINICAL TRIAL DATA
    • 3.12     PORTER’S FIVE FORCE ANALYSIS
      • 3.12.1      THREAT OF NEW ENTRANTS
      • 3.12.2     THREAT OF SUBSTITUTES
      • 3.12.3     BARGAINING POWER OF SUPPLIERS
      • 3.12.4     BARGAINING POWER OF BUYERS
      • 3.12.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.13     SUPPLY CHAIN ANALYSIS
    • 3.14     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.14.1      GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.14.2     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.14.3     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.14.4     LAB-BASED GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
  • 4     GLUCOSE MONITORING GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     INVASIVE GLUCOSE MONITORING
    • 4.3     SELF GLUCOSE MONITORING
      • 4.3.1     BLOOD GLUCOSE METER
      • 4.3.2     BLOOD GLUCOSE TESTING STRIPS
      • 4.3.3     LANCETS
      • 4.3.4     OTHERS
    • 4.4     CONTINUOS GLUCOSE MONITORING
      • 4.4.1     GLUCOSE SENSORS
      • 4.4.2     TRANSMITTERS AND RECEIVERS
    • 4.5     NON-INVASIVE GLUCOSE MONITORING
    • 4.6     LAB BASED GLUCOSE MONITORING
  • 5     GLUCOSE MONITORING GLOBAL MARKET, BY SAMPLE SOURCE
    • 5.1     INTRODUCTION
    • 5.2     BLOOD BASED GLUCOSE MONITORING
    • 5.3     URINE BASED GLUCOSE MONITORING
    • 5.4     OTHER SOURCES BASED GLUCOSE MONITORING
  • 6     GLUCOSE MONITORING GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS
    • 6.3     HOME CARE
    • 6.4     PRIVATE CLINICS
    • 6.5     AMBULATORY SETTINGS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     OTHERS
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     U.K.
      • 7.3.3     FRANCE
      • 7.3.4     OTHERS
    • 7.4     ASIA - PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     OTHERS
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     MIDDLE EAST & OTHERS
      • 7.5.3     REST OF LATIN AMERICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     APPROVALS
    • 8.3     NEW PRODUCT LAUNCHES
    • 8.4     AGREEMENTS, ACQUISITIONS & COLLABORATION
    • 8.5     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES, INC
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AGAMATRIX, INC.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     ARKRAY, INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     ASCENSIA DIABETES CARE HOLDINGS AG.
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     B.BRAUN MELSUNGEN AG
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     BIO-RAD LABORATORIES
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     DEXCOM INC.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     JOHNSON & JOHNSON
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     MEDTRONIC, PLC
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     TRIVIDIA HEALTH, INC.
      • 9.10.1      OVERVIEW
      • 9.10.2      FINANCIALS
      • 9.10.3      PRODUCT PORTFOLIO
      • 9.10.4      KEY DEVELOPMENTS
      • 9.10.5      BUSINESS STRATEGY
      • 9.10.6       SWOT ANALYSIS
    • 9.11     ROCHE HOLDINGS AG
      • 9.11.1      OVERVIEW
      • 9.11.2      FINANCIALS
      • 9.11.3      PRODUCT PORTFOLIO
      • 9.11.4      KEY DEVELOPMENTS
      • 9.11.5      BUSINESS STRATEGY
      • 9.11.6      SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 2     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 3     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 4     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE,BY REGION (2015 - 2023) ($MN)
      • TABLE 5     SELF GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 6     SELF GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 7     BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 8     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 9     LANCETS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 10     OTHERS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 11     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 12     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE,BY REGION (2015 - 2023) ($MN)
      • TABLE 13     GLUCOSE SENSORS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 14     TRANSMITTER AND RECEIVERS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 15     NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 16     LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 17     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2015-2023) ($MN)
      • TABLE 18     BLOOD BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 19     URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 20     OTHER SOURCE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 21     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY END-USER (2015-2023) ($MN)
      • TABLE 22     GLUCOSE MONITORING HOSPITAL GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 23     GLUCOSE MONITORING HOME CARE GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 24     GLUCOSE MONITORING PRIVATE CLINICS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 25     GLUCOSE MONITORING AMBULATORY SETTINGS GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 26     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • TABLE 27     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 28     NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 29     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 30     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 31     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2015-2023) ($MN)
      • TABLE 32     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2015-2023) ($MN)
      • TABLE 33     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 34     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 35     EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 36     EUROPE SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 37     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 38     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2015-2023) ($MN)
      • TABLE 39     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2015-2023) ($MN)
      • TABLE 40     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 41     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 42     ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 43     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 44     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 45     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2015-2023) ($MN)
      • TABLE 46     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2015-2023) ($MN)
      • TABLE 47     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 48     ROW GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 49     ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 50     ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015- 2023) ($MN)
      • TABLE 51     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 52     ROW GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2015-2023) ($MN)
      • TABLE 53     ROW GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2015-2023) ($MN)
      • TABLE 54     ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 55     APPROVALS (2016-2017)
      • TABLE 56     NEW PRODUCT LAUNCHES (2016-2017)
      • TABLE 57     AGREEMENTS, ACQUISITIONS & COLLABORATION (2016-2017)
      • TABLE 58     OTHERS (2016-2017)
      • TABLE 59     ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 60     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 61     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 62     B BRAUN MELSUNGEN: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 63     B BRAUN MELSUNGEN: TOTAL REVENUE, BY SEGMENTS (2014-2016) ($MN)
      • TABLE 64     B BRAUN MELSUNGEN: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 65     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 66     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 67     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 68     DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 69     DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 70     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 71     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 72     JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICES SEGMENTS, (2014-2016) ($MN)
      • TABLE 73     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 74     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 75     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 76     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 77     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 78     ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 79     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BY TYPES, (2014-2016) ($MN)
      • TABLE 80     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
      • FIGURE 3     GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BY MAJOR PLAYERS (2012-2017)
      • FIGURE 9     GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
      • FIGURE 10     GLUCOSE MONITORING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 12     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 13     CONTINUIUOS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 14     LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2016
      • FIGURE 15     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 16     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2016) ($MN)
      • FIGURE 17     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 18     INVASIVE GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2016 V/S 2023) (%)
      • FIGURE 19     SELF GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 20     SELF GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 21     BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 22     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 23     LANCETS GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 24     OTHERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • FIGURE 25     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 26     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • FIGURE 27     GLUCOSE SENSORS GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 28     TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 29     NON-INVASIVE DEVICE RESEARCH FOCUS BASED ON SOURCE
      • FIGURE 30     NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 31     LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • FIGURE 32     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 33     BLOOD BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 34     URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 35     OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016 V/S 2023) ($MN)
      • FIGURE 36     GLUCOSE MONITORING GLOBAL MARKET SHARE, BY END -USER (2016) (%)
      • FIGURE 37     GLUCOSE MONITORING HOSPITAL GLOBAL MARKET REVENUE, BY END -USER (2016 V/S 2023) ($MN)
      • FIGURE 38     GLUCOSE MONITORING HOME CARE GLOBAL MARKET REVENUE, BY END -USER (2016 V/S 2023) ($MN)
      • FIGURE 39     GLUCOSE MONITORING PRIVATE CLINICS GLOBAL MARKET REVENUE, BY END -USER (2016 V/S 2023) ($MN)
      • FIGURE 40     GLUCOSE MONITORING AMBULATORY SETTINGS GLOBAL MARKET REVENUE, BY END -USER (2016 V/S 2023) ($MN)
      • FIGURE 41     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2015 - 2023) ($MN)
      • FIGURE 42     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016) ($MN)
      • FIGURE 43     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 44     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 45     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 46     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 47     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • FIGURE 48     U.S. GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 49     U.S. GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 50     OTHERS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCT, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 51     OTHERS GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 52     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016) ($MN)
      • FIGURE 53     EUROPE SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 54     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 55     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 56     EUROPE GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 57     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • FIGURE 58     GERMANY GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 59     GERMANY GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 60     U.K. GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 61     U.K. GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 62     FRANCE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 63     FRANCE GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 64     OTHER GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 65     OTHERS GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 66     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016) ($MN)
      • FIGURE 67     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 68     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 69     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 70     ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 71     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • FIGURE 72     JAPAN GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 73     JAPAN GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 74     CHINA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 75     CHINA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 76     INDIA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 77     INDIA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 78     OTHER GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 79     OTHERS GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 80     ROW GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016) ($MN)
      • FIGURE 81     ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) ($MN)
      • FIGURE 82     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • FIGURE 83     ROW GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 84     ROW GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 85     ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • FIGURE 86     BRAZIL GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 87     BRAZIL GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 88     MIDDLE EAST GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (2016 V/S 2023) ($MN)
      • FIGURE 89     MIDDLE EAST GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 90     REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2016 VS 2023) ($MN), BY SAMPLE SOURCE (20162 V/S 2023) ($MN)
      • FIGURE 91     REST OF LATIN AMERICA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2016) (%)
      • FIGURE 92     KEY GROWTH STRATEGIES (2016 – 2017)
      • FIGURE 93     APPROVALS BY MAJOR COMPANIES (2016-2017)
      • FIGURE 94     NEW PRODUCT LAUNCH BY MAJOR COMPANIES (2016-2017)
      • FIGURE 95     AGREEMENTS, ACQUISITIONS & COLLABORATION BY MAJOR COMPANIES (2016-2017)
      • FIGURE 96     OTHER DEVELOPMENTS (2016-2017)
      • FIGURE 97     SWOT: ABBOTT LABORATORIES
      • FIGURE 98     SWOT: AGAMATRIX, INC
      • FIGURE 99     SWOT: ARKRAY, INC
      • FIGURE 100     SWOT: ASCENSIA DIABETES CARE
      • FIGURE 101     SWOT: B BRAUN MELSUNGEN
      • FIGURE 102     SWOT: BIO-RAD LABORATORIES
      • FIGURE 103     SWOT: DEXCOM INC.
      • FIGURE 104     SWOT: JOHNSON & JOHNSON
      • FIGURE 105     SWOT: MEDTRONIC, PLC
      • FIGURE 106     SWOT: TRIVIDIA HEALTH, INC
      • FIGURE 107     SWOT: ROCHE HOLDINGS AG

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT LABORATORIES
      • 2     ACON DIABETES CARE INTERNATIONAL
      • 3     ADALTIS S.R.L.
      • 4     AGAMATRIX, INC.
      • 5     ALERE INC.
      • 6     ALLIANCE INTERNATIONAL CO., LTD.
      • 7     ALLMEDICUS CO., LTD.
      • 8     ARKRAY, INC.
      • 9     ASCENSIA DIABETES CARE HOLDINGS AG
      • 10     B. BRAUN MELSUNGEN AG
      • 11     BECTON DICKINSON AND COMPANY
      • 12     BEIJING YICHENG BIOELECTRONICS TECHNOLOGY CO., LTD.
      • 13     BEURER GMBH
      • 14     BHAT BIO-TECH INDIA (P) LTD
      • 15     BIOCHEMICAL SYSTEMS INTERNATIONAL
      • 16     BIOLAND TECHNOLOGY LTD.
      • 17     BIONIME CORPORATION
      • 18     BIOPTIK TECHNOLOGY INC.
      • 19     BIORAD LABORATORIES, INC.
      • 20     BIOTEST MEDICAL CORPORATION
      • 21     BIOVOTION AG
      • 22     BODYTEL GMBH
      • 23     BREMED LIMITED
      • 24     CALISTO MEDICAL, INC.
      • 25     CAREMATIX INC
      • 26     CHUNGDO PHARM. CO., LTD.
      • 27     CONTEC MEDICAL SYSTEMS
      • 28     CONVERGENT TECHNOLOGIES
      • 29     CRF HEALTH
      • 30     DANAHER CORPORATION
      • 31     DARIOHEALTH CORP
      • 32     DEXCOM, INC.
      • 33     DIABETOMICS, INC.
      • 34     DIAMONTECH GMBH
      • 35     DIRAMED, LLC
      • 36     DNURSE TECHNOLOGY CO. LTD
      • 37     ECHO THERAPEUTICS, INC.
      • 38     EKF DIAGNOSTICS
      • 39     EMSIG GMBH CO.
      • 40     ENTRA HEALTH SYSTEMS LLC
      • 41     ERBA DIAGNOSTICS
      • 42     ETERNITY HEALTHCARE
      • 43     FIA BIOMED GMBH
      • 44     FORA CARE, INC
      • 45     FORACARE SUISSE AG
      • 46     FREEDOM MEDITECH, INC
      • 47     GENERAL LIFE BIOTECHNOLOGY CO., LTD.
      • 48     GENESIS HEALTH TECHNOLOGIES
      • 49     GLUCOSENSE DIAGNOSTICS LTD
      • 50     GLUCOSTRATUS LTD.
      • 51     GLYSENS INCORPORATED
      • 52     GLYSURE LTD.
      • 53     GREINER BIO-ONE
      • 54     HANGZHOU SEJOY ELECTRONICS & INSTRUMENTS CO. LTD. 
      • 55     HENIZ HERENZ MEDIZINALBEDARF GMBH
      • 56     HTL-STREFA S.A.
      • 57     HUBDIC
      • 58     IHEALTH LABS INC.
      • 59     IME-DC GMBH
      • 60     IN4 TECHNOLOGY CORP.
      • 61     INFOPIA CO LTD
      • 62     INSIDE BIOMETRICS LTD
      • 63     INTEGRITY APPLICATIONS
      • 64     INTERNATIONAL BIOMEDICAL
      • 65     INTUITY MEDICAL, INC
      • 66     I-SENS, INC.
      • 67     JIANGSU FOLEE MEDICAL EQUIPMENT LIMITED COMPANY
      • 68     JIANGSU HUIDA MEDICAL INSTRUMENTS CO LTD
      • 69     JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.
      • 70     JOHNSON & JOHNSON
      • 71     K-JUMP HEALTH CO., LTD
      • 72     LEIN APPLIED DIAGNOSTICS LTD.
      • 73     LEMM TECHNOLOGIES, LLC.
      • 74     LIFOTRONIC TECHNOLOGY CO., LTD.
      • 75     LIGHTOUCH MEDICAL INC
      • 76     LOBECK MEDICAL AG
      • 77     L-TAC MEDICARE PTE LTD
      • 78     MEDULLA HEALTH INC
      • 79     MEDISANA AG 
      • 80     MEDIWISE
      • 81     MEDTRONIC, INC.
      • 82     A. MENARINI DIAGNOSTICS  LTD.
      • 83     NATIONAL DIAGNOSTIC PRODUCTS PTY LTD.
      • 84     NEMAURA MEDICAL INC.
      • 85     NOVA BIOMEDICAL
      • 86     NOVIOSENSE BV
      • 87     NU-BECA & MAXCELLENT CO.
      • 88     OK BIOTECH CO. , LTD
      • 89     OPTICOLOGY, INC.
      • 90     OWEN MUMFORD LTD
      • 91     PEPEX BIOMEDICAL, INC.
      • 92     PHARMA TECH SOLUTIONS INC.
      • 93     POP TEST LLC
      • 94     PRODIGY DIABETES CARE, LLC
      • 95     QUICK LLC
      • 96     RAINBOW MEDICAL INNOVATION LTD.
      • 97     ROCHE HOLDING AG
      • 98     ROMED HOLLAND
      • 99     SAIFY TRADERS
      • 100     SAIF CARE
      • 101     SANOFI S.A.
      • 102     SARSTEDT
      • 103     SENSEONICS
      • 104     SENTEC PTE LTD
      • 105     SIEMENS AG
      • 106     STAIRWAY LABORATORIES INC
      • 107     SYSMEX CORPORATION
      • 108     TAIDOC TECHNOLOGY CORPORATION.
      • 109     TEAR GLUCOSE RESEARCH, LLC
      • 110     TERUMO CORPORATION
      • 111     THERMO FISHER SCIENTIFIC
      • 112     TRINITY BIOTECH PLC
      • 113     TRIVIDIA HEALTH, INC
      • 114     TRULY INSTRUMENT LIMITED
      • 115     VISGENEER INC.
      • 116     VISIOMED GROUP
      • 117     VIVACHEK LABORATORIES, INC.
      • 118     XHALE, INC.
      • 119     YPSOMED AG
      • 120     ZHEJIANG POCTECH CO.,LTD.
      • 121     ZIVAK TECHNOLOGY